Dubuisson A, Micheau O. Antibodies and derivatives targeting DR4 and DR5 for cancer therapy. Antibodies. 2017;6(4):16.

Article  PubMed  PubMed Central  Google Scholar 

Di Cristofano F, George A, Tajiknia V, et al. Therapeutic targeting of TRAIL death receptors. Biochem Soc Trans. 2023;51(1):57–70.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Allen JE, Krigsfeld G, Patel L, et al. Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway. Mol Cancer. 2015;14:99.

Article  PubMed  PubMed Central  Google Scholar 

Xin DE, Liao Y, Rao R, et al. Chaetocin-mediated SUV39H1 inhibition targets stemness and oncogenic networks of diffuse midline gliomas and synergizes with ONC201. Neuro Oncol. 2024;26(4):735–48.

Article  PubMed  CAS  Google Scholar 

Zhang Y, Zhou L, Safran H, et al. EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG. Neoplasia. 2021;23(8):792–810.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zhou L, Zhang L, Zhang J, et al. Imipridones ONC201/ONC206 + RT/TMZ triple (IRT) therapy reduces intracranial tumor burden, prolongs survival in orthotopic IDH-WT GBM mouse model, and suppresses MGMT. Oncotarget. 2025;16:230–48.

Article  PubMed  PubMed Central  Google Scholar 

Chimerix. Chimerix announces FDA acceptance and Priority Review of New Drug Application for dordaviprone as treatment for recurrent H3 K27M-mutant diffuse glioma [media release]. 18 Feb 2025. http://www.chimerix.com.

Oncoceutics. FDA grants Fast Track Designation to ONC201 for the treatment of adult recurrent H3 K27M-mutant high-grade glioma [media release]. 12 Nov 2018. http://www.oncoceutics.com.

Oncoceutics. FDA grants Rare Pediatric Disease Designation to ONC201 for the treatment of H3 K27M-mutant glioma [media release]. 21 Jul 2020. http://www.oncoceutics.com.

US Food & Drug Administration. FDA grants accelerated approval to dordaviprone for diffuse midline glioma [media release]. 6 Aug 2025. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dordaviprone-diffuse-midline-glioma.

Jazz Pharmaceuticals Inc. MODEYSO™ (dordaviprone) capsules, for oral use: US prescribing information. 2025. https://pp.jazzpharma.com/pi/modeyso.en.USPI.pdf. Accessed 17 Sep 2025.

Oncoceutics. Oncoceutics and Calvert Research announce investment partnership to advance ONC201 to an IND filing [media release]. 3 Oct 2013. http://www.oncoceutics.com.

Oncoceutics. Oncoceutics and Frontida BioPharm announce product development and commercialization partnership [media release]. 16 Jan 2018. http://www.oncoceutics.com.

Oncoceutics. Oncoceutics licenses rights to ONC201 for Japan to Ohara Pharmaceutical Co., Ltd [media release]. 15 Feb 2019. http://www.oncoceutics.com.

Oncoceutics. Oncoceutics licenses rights to ONC201 for Greater China to China Resources Sanjiu Medical Pharmaceutical Co., Ltd [media release]. 15 Dec 2020. http://www.oncoceutics.com.

Oncoceutics. Oncoceutics announces first patent issued for novel anti-cancer drug ONC201 [media release]. 16 Apr 2014. http://www.oncoceutics.com.

Oncoceutics. Oncoceutics announces USPTO reissues patent with correct structure of ONC201 [media release]. 31 Jan 2017. http://www.oncoceutics.com.

Oncoceutics. U.S. patent issued for ONC201 composition of matter [media release]. 24 Feb 2016. http://www.oncoceutics.com.

Oncoceutics. Oncoceutics expands patent family to include use of ONC201 in H3 K27M-mutant gliomas [media release]. 14 Jan 2019. http://www.oncoceutics.com.

Oncoceutics. Additional composition of matter patent in China expands ONC201's global coverage [media release]. 26 Mar 2020. http://www.oncoceutics.com.

Oncoceutics. Oncoceutics extends IP coverage to Japan with new patent covering all cancers [media release]. 8 Jan 2018. http://www.oncoceutics.com

Oncoceutics. Oncoceutics expands IP portfolio with additional patents for ONC201 and ONC212 [media release]. 12 Oct 2020. http://www.oncoceutics.com.

Free RB, Cuoco CA, Xie B, et al. Pharmacological characterization of the imipridone anticancer drug ONC201 reveals a negative allosteric mechanism of action at the D(2) dopamine receptor. Mol Pharmacol. 2021;100(4):372–87.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Przystal JM, Cianciolo Cosentino C, Yadavilli S, et al. Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas. Neuro Oncol. 2022;24(9):1438–51.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Allen JE, Kline CL, Prabhu VV, et al. Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget. 2016;7(45):74380–92.

Article  PubMed  PubMed Central  Google Scholar 

Allen JE, Krigsfeld G, Mayes PA, et al. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med. 2013;5(171):171ra17.

Article  PubMed  PubMed Central  Google Scholar 

Allen JE, Crowder RN, El-Deiry WS. First-in-class small molecule ONC201 induces DR5 and cell death in tumor but not normal cells to provide a wide therapeutic index as an anti-cancer agent. PLoS One. 2015;10(11):e0143082.

Article  PubMed  PubMed Central  Google Scholar 

Stein MN, Malhotra J, Tarapore RS, et al. Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration. J Immunother Cancer. 2019;7(1):136.

Article  PubMed  PubMed Central  Google Scholar 

Stein MN, Bertino JR, Kaufman HL, et al. First-in-human clinical trial of oral ONC201 in patients with refractory solid tumors. Clin Cancer Res. 2017;23(15):4163–9.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Faison SL, Batonga J, Arumugham T, et al. A phase 1 randomized study to evaluate the safety, tolerability, and pharmacokinetics of single escalating oral doses of dordaviprone and the effects of food on the bioavailability of dordaviprone in healthy adult subjects. Clin Pharmacol Drug Dev. 2025;14(5):382–90.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Teffera Y, Tippin T, Bartkus A, et al. A phase 1 study to evaluate the absorption, metabolism, and disposition of dordaviprone in healthy adult participants. Clin Pharmacol Drug Dev. 2025;14(7):549–56.

Article  PubMed  CAS  Google Scholar 

Faison SL, Batonga J, Arumugham T, et al. Effect of severe renal impairment on dordaviprone (ONC201) pharmacokinetics. Drugs R D. 2025. https://doi.org/10.1007/s40268-025-00520-x.

Article  PubMed  PubMed Central  Google Scholar 

Faison SL, Batonga J, Arumugham T, et al. A phase 1, randomized, crossover trial to assess the effect of itraconazole on the pharmacokinetics of dordaviprone in healthy adults. Br J Clin Pharmacol. 2025. https://doi.org/10.1002/bcp.70080.

Article  PubMed  Google Scholar 

Faison SL, Batonga J, Arumugham T, et al. Relative bioavailability of dordaviprone (ONC201) is not affected by co-administration of the proton-pump inhibitor rabeprazole. J Clin Pharmacol. 2025;65(4):520–6.

Article  PubMed  CAS  Google Scholar 

Odia Y, Koschmann C, Vitanza NA, et al. Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma. Neuro Oncol. 2024;26(Suppl_2):S155–64.

Article  PubMed  PubMed Central  Google Scholar 

Venneti S, Kawakibi AR, Ji S, et al. Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways. Cancer Discov. 2023;13(11):2370–93.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sumrall A, Allen J, Bagley S, et al. Efficacy and safety of dordaviprone (ONC201) in prospective clinical trials of adult and pediatric recurrent H3 K27M-mutant diffuse glioma patients [abstract no. 10017]. J Clin Oncol. 2025;43(16 Suppl).

Arrillaga-Romany I, Gardner SL, Odia Y, et al. ONC201 (dordaviprone) in recurrent H3 K27M-mutant diffuse midline glioma. J Clin Oncol. 2024;42(13):1542–52.

Article  PubMed  CAS  Google Scholar 

Kline C, Franson A, Banerjee A, et al. TRLS-14. PNOC022 report: a combination therapy trial using an adaptive platform design for patients with diffuse midline glioma at initial diagnosis, postradiation therapy, or progression. Neuro Oncol. 2024;26(Suppl 4):iv48.

Google Scholar 

Arrillaga-Romany I, Chi AS, Allen JE, et al. A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma. Oncotarget. 2017;8(45):79298–304.

Article  PubMed  PubMed Central  Google Scholar 

Atkins SLP, Greer YE, Jenkins S, et al. A single-arm, open-label phase II study of ONC201 in recurrent/refractory metastatic breast cancer and advanced endometrial carcinoma. Oncologist. 2023;28(10):919-e72.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Almhanna K, Breakstone R, Raufi A, et al. Nivolumab plus ONC201 plus in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) patients: a Brown University Oncology Research Group phase Ib/II study (BrUOG379). Transl Gastroenterol Hepatol. 2024;9:15.

Article  PubMed  PubMed Central